Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
The FDA has granted Fast Track designation for elritercept for very low-, low- and intermediate-risk MDS.On Tuesday, Takeda Pharmaceutical Company Limited (NYSE:TAK) entered into an exclusive licensing agreement with Keros Therapeutics, Inc. (NASDAQ:KROS) to further develop, manufacture and commercialize elritercept worldwide outside of mainland China, Hong Kong and Macau.
星期二，武田制药股份有限公司（纽交所：TAK）与keros therapeutics公司（纳斯达克：KROS）签署了一项独家许可协议，以进一步开发、制造和全球商业化elritercept，在中国大陆、香港和澳门之外的世界范围内。
Elritercept is a late-stage investigational activin inhibitor designed to treat anemia associated with certain hematologic cancers, including myelodysplastic syndromes and myelofibrosis.
Elritercept是一种已进入晚期研究的activin抑制剂，旨在治疗与某些血液学癌症相关的贫血，包括骨髓增生异常综合症和骨髓纤维化。
Also Read: Analyst Sees Keros Therapeutics As Next Acceleron, the Set For Major Biotech Growth
分析师认为Keros Therapeutics是下一个Acceleron，为主要生物技术增长做准备
The FDA has granted Fast Track designation for elritercept for very low-, low- and intermediate-risk MDS.
FDA已授予elritercept用于治疗非常低风险、低风险和中等风险骨髓增生异常的快速通道认定。
Myelodysplastic syndromes and myelofibrosis are characterized by inadequate blood cell production, often leading to severe anemia.
骨髓增生异常综合症和骨髓纤维化的特点是血细胞生产不足，常常导致严重贫血。
Elritercept targets activin A and B proteins, which are believed to be crucial in anemia-associated diseases.
Elritercept作用靶点是activin A和b蛋白，据信在与贫血相关的疾病中至关重要。
In early clinical studies, elritercept has shown promising clinical activity and a manageable safety profile in patients with very low-, low- and intermediate-risk myelodysplastic syndromes as a monotherapy and in patients with myelofibrosis in combination with standard of care.
在早期临床研究中，elritercept在非常低风险、低风险和中等风险骨髓增生异常患者中作为单药疗法以及在与标准治疗联合应用下治疗骨髓纤维化患者方面显示出有希望的临床活性和可管理的安全性。
Elritercept is currently in two ongoing Phase 2 trials for very low-, low- or intermediate-risk myelodysplastic syndromes and myelofibrosis patients.
Elritercept目前正在进行两项针对非常低、低或中度骨髓增生异常和骨髓纤维化患者的进行中2期临床试验。
The Phase 3 RENEW trial evaluating elritercept in adult patients with transfusion-dependent anemia with very low-, low- or intermediate-risk myelodysplastic syndromes will begin enrollment soon.
RENEW试验的第3阶段将很快开始招募，评估elritercept在成年患有输血依赖性贫血的患者中的应用，这些患者患有非常低、低或中等风险的骨髓增殖异常综合征。
Takeda plans to evaluate elritercept in these cancers across patient segments and lines of therapy.
武田计划在患者细分群和治疗线中评估elritercept在这些癌症中的应用。
Takeda will pay Keros Therapeutics an upfront payment of $200 million and is eligible to receive milestones with the potential to exceed $1.1 billion. Keros will also be eligible to receive tiered royalties on net sales.
武田将向Keros Therapeutics支付20000万美元的预付款，并有资格获得超过11亿美元的里程碑。Keros还有资格根据净销售额获得分阶段的版税。
William Blair writes that With Takeda taking responsibility for elritercept development, Keros (Outperform rating) will now have two wholly owned assets, including cibotercept in pulmonary arterial hypertension and KER-065 in obesity and neuromuscular indications, allowing Keros to narrow its focus.
William Blair指出，随着武田负责elritercept的开发，Keros（表现优异评级）现在将拥有两个全部拥有的资产，包括治疗肺动脉高压的cibotercept和治疗肥胖症和神经肌肉疾病的KER-065，这使Keros能够专注于其核心业务。
The analyst notes that multiple offers for elritercept were received. Management believes that Takeda is aligned with its views on the broader opportunity for elritercept.
分析师指出，收到了多个有关elritercept的要约。管理层认为武田与其在elritercept的广阔机会上的观点一致。